Ship Inhibition to Direct Hematopoietic Stem Cells and Induce Extramedullary Hematopoiesis

• US 20100136026A1
• Filed: 09/26/2008
• Published: 06/03/2010
• Est. Priority Date: 09/26/2007
• Status: Abandoned Application

• Current Assignee: University of South Florida (State University System of Florida)
• Original Assignee: University of South Florida (State University System of Florida)
• Inventors: Hazen, Amy, Kerr, William G.
• Application Number:
  US12/670,360
• Publication Number:
  US 20100136026A1
• Time in Patent Office: Days
• US Class Current: 424/158.100
• CPC Class Codes: A61K 2300/00 Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
• CPC Class Codes: A61K 38/1816 Erythropoietin [EPO]
• CPC Class Codes: A61K 38/193 Colony stimulating factors [CSF]
• CPC Class Codes: A61P 19/08 for bone diseases, e.g. rachitism, Paget's disease
• CPC Class Codes: C12N 15/1137 against enzymes viral enzymes C12N15/1131; receptors C12N15/1138
• CPC Class Codes: C12N 2310/14 interfering N.A.

Abstract

The present invention concerns inhibition of SHIP expression and/or function in mammalian subjects to direct HSC from the bone marrow to other sites in the body (such as the spleen and/or liver), where they then re-establish blood cell production. The method of the invention can be employed, for example, to rescue or enhance blood cell recovery during bone marrow impairment due to bone-seeking radioisotope exposure, chemotherapy, radiotherapy, infection, or genetic or congenital defects. Preferably, inhibition of SHIP expression and/or function is achieved by administering an effective amount of one or more SHIP inhibitors to the subject. In one embodiment, the subject is suffering from, or at risk of developing, bone marrow failure (such as an aplastic bone marrow failure syndrome). In another embodiment, the subject is suffering from, or at risk of, exposure to a bone-seeking radioisotope. In another embodiment, the subject is suffering from, or at risk of developing, fibrotic or damaged bone marrow due to chemotherapy and/or radiation therapy for cancer.

Claims

1. A method for directing hematopoietic stem cells (HSC) from bone marrow to another site in the body of a person or animal, wherein said method comprises inhibiting SHIP expression and/or SHIP function or activity in a cell of the person or animal, such that the HSC are directed to another site in the body.

2. The method according to claim 1, wherein SHIP expression is inhibited by RNA interference, or antisense inhibition, or ribozyme inactivation, or an antibody or other molecule that inhibits function or activity of SHIP.

4. The method according to claim 1, wherein the person or animal has radiation injury manifesting as impaired bone marrow function, or was exposed to, or is at risk of exposure to, a radioisotope that can accumulate in bone.

6. The method according to claim 1, wherein the person or animal has, or is at risk of developing, fibrotic and/or damaged bone marrow due to chemotherapy and/or radiation therapy.

7. The method according to claim 1, wherein the person or animal is being treated with one or more other treatments to increase hematopoietic function.

9. The method according to claim 1, wherein the HSC are directed from bone marrow to the spleen and/or liver.

11. The method according to claim 1, wherein the person or animal has an infection or a genetic or congenital defect that impairs bone marrow function.

14. The method according to claim 1, wherein the person or animal has bone marrow impairment that results from Fanconi anemia, dyskeratosis congenital, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, aplastic anemia, MDS, PRCA, or myelophthisis.

3. (canceled)

5. (canceled)

8. (canceled)

10. (canceled)

12-13. -13. (canceled)

15-16. -16. (canceled)

17. A method for rescuing or enhancing blood cell recovery during bone marrow impairment in a person or animal, wherein said method comprises inhibiting SHIP expression and/or SHIP function or activity in a cell of the person or animal.

20. The method according to claim 17, wherein the bone marrow impairment results from Fanconi anemia, dyskeratosis congenital, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, aplastic anemia, MDS, PRCA, or myelophthisis.

21. The method according to claim 17, wherein SHIP expression is inhibited by RNA interference, or antisense inhibition, or ribozyme inactivation, or an antibody or other molecule that inhibits function or activity of SHIP.

23. The method according to claim 17, wherein the person or animal has radiation injury manifesting as impaired bone marrow function, or was exposed to, or is at risk of exposure to, a radioisotope that can accumulate in bone.

25. The method according to claim 17, wherein the person or animal has, or is at risk of developing, fibrotic and/or damaged bone marrow due to chemotherapy and/or radiation therapy.

26. The method according to claim 17, wherein the person or animal is being treated with one or more other treatments to increase hematopoietic function.

28. The method according to claim 17, wherein HSC are directed from bone marrow to the spleen and/or liver.

30. The method according to claim 17, wherein the person or animal has an infection or a genetic or congenital defect that impairs bone marrow function.

18-19. -19. (canceled)

22. (canceled)

24. (canceled)

27. (canceled)

29. (canceled)

31-32. -32. (canceled)

33. A method for treating or delaying the onset of impaired bone marrow function in a person or animal, wherein said method comprises administering a therapeutically effective amount of a SHIP inhibitor to a person or animal in need of treatment.

34. The method according to claim 33, wherein SHIP expression is inhibited by RNA interference, or antisense inhibition, or ribozyme inactivation, or an antibody or other molecule that inhibits function or activity of SHIP.

36. The method according to claim 33, wherein the person or animal has radiation injury manifesting as impaired bone marrow function, or was exposed to, or is at risk of exposure to, a radioisotope that can accumulate in bone.

38. The method according to claim 33, wherein the person or animal has, or is at risk of developing, fibrotic and/or damaged bone marrow due to chemotherapy and/or radiation therapy.

39. The method according to claim 33, wherein the person or animal is being treated with one or more other treatments to increase hematopoietic function.

41. The method according to claim 33, wherein the HSC are directed from bone marrow to the spleen and/or liver.

43. The method according to claim 33, wherein the person or animal has an infection or a genetic or congenital defect that impairs bone marrow function.

46. The method according to claim 33, wherein the person or animal has bone marrow impairment that results from Fanconi anemia, dyskeratosis congenital, Diamond-Blackfan anemia, Shwachman-Diamond syndrome, aplastic anemia, MDS, PRCA, or myelophthisis.

35. (canceled)

37. (canceled)

40. (canceled)

42. (canceled)

44-45. -45. (canceled)

47-48. -48. (canceled)